TRVI - NASDAQ
Trevi Therapeutics, Inc.
$13.45
-3.6%Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
At a Glance
Live SnapshotTrevi Therapeutics, Inc. Management Team
Mr. Farrell Simon Pharm.D.
Chief Commercial Officer
Dr. James V. Cassella Ph.D.
Chief Development Officer
Compensation
$671,632
Ms. Lisa Delfini
Chief Financial Officer
Compensation
$604,679
Dr. Thomas R. Sciascia M.D.
Co-Founder & Chief Scientific Officer
Compensation
$551,426
Ms. Jennifer L. Good
Co-Founder, Chief Executive Officer, President & Director
Compensation
$987,254
Katie McManus
Communications Manager
Mr. Christopher Galletta
Controller & Chief Accounting Officer
Trevi Therapeutics, Inc. Insider Positioning
During the last 12 months, insiders have purchased $1.41M worth of TRVI shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
225.0K
1.41M
0
0.00
+1.4M
+$1.41M
Top Buyers
Mathers Edward T
Director
$281K
Colangelo Dominick
Director
$281K
Heffernan Michael Thomas
Director
$281K
Vanlent Anne
Director
$281K
Meeker David P
Director
$281K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $1.41M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
5 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
TRVI - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 21, 2026 | April 21, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 29, 2025 | April 29, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 13, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | May 01, 2023 | June 28, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 23, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 27, 2021 | June 16, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 11, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.